Article Information
History
- August 4, 2022.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. All rights reserved. No reuse allowed without permission.
Author Information
- Nina Nguyen, MD1,#,
- Sana Chaudhry, BSc1,#,
- Tulasigeri M. Totiger, PhD1,#,
- Robert Diaz, MS1,
- Evan Roberts, BSc1,
- Skye Montoya, BSc1,
- Gabriel Pardo, BSc1,
- Alejandro Pardo, BSc1,
- Jumana Afaghani, BSc1,
- Maurizio Affer, MSc1,
- Jacob Jahn, BSc1,
- Terrence Bradley, MD3,
- Francesco Maura, MD2,
- Dickran Kazandjian, MD2,
- Daniel Bilbao, PhD1,
- Jennifer Chapman, MD4,
- Ola Landgren, MD,PhD2,
- James Hoffman, MD2,* and
- Justin Taylor, MD3,*
- 1Sylvester Comprehensive Cancer Center at the University of Miami Miller School of Medicine
- 2Myeloma Division, Department of Medicine, University of Miami Miller School of Medicine
- 3Leukemia Program, Department of Medicine, University of Miami Miller School of Medicine
- 4Department of Pathology, University of Miami Miller School of Medicine
- ↵*Correspondence:
James Hoffman, j.hoffman4{at}med.miami.edu, Justin Taylor, jxt1091{at}miami.edu
↵# Equal contribution
Posted August 04, 2022.
Combination Venetoclax and Selinexor Effective in Relapsed Refractory Multiple Myeloma with Translocation t(11;14)
